Nova Patents
IL277252B2

Triazacyclododecansulfonamide (" tcd" )-based protein secretion inhibitors

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

Every citation, both ways

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
WO02080856A2CitesWorld Intellectual Property Organization (WIPO)XYSearch report1,3-4,20-21,33
WO9625167A1CitesWorld Intellectual Property Organization (WIPO)XYSearch report1,3-4,20-21,33
WO9725167A1CitesWorld Intellectual Property Organization (WIPO)XYSearch report1,3-4,20-21,33
CHAWLA, REENA, ET AL., TUNING SIDE ARM ELECTRONICS IN UNSYMMETRICAL CYCLOTRIAZADISULFONAMIDE (CADA) ENDOPLASMIC RETICULUM (ER) TRANSLOCATION INHIBITORS TO IMPROVE THEIR HUMAN CLUSTER OF DIFFERENTIATION 4 (CD4) RECEPTOR DOWN-MODULATING POTENCIES., 14 March 2016 (2016-03-14)Non-patent––Search report–
VAN PUYENBROECK, VICTOR, ET AL., A PROTEOMIC SURVEY INDICATES SORTILIN AS A SECONDARY SUBSTRATE OF THE ER TRANSLOCATION INHIBITOR CYCLOTRIAZADISULFONAMIDE (CADA)., 31 December 2017 (2017-12-31)Non-patent––Search report–
CHERNICHENKO, NATALIYA M., ET AL., SYNTHESIS OF DANSYL-SUBSTITUTED CRYPTANDS CONTAINING TRIAZACYCLOALKANE MOIETIES AND THEIR EVALUATION AS FLUORESCENT CHEMOSENSORS., 21 September 2017 (2017-09-21)Non-patent––Search report–
DEMILLO, VIOLETA G., ET AL., UNSYMMETRICAL CYCLOTRIAZADISULFONAMIDE (CADA) COMPOUNDS AS HUMAN CD4 RECEPTOR DOWN-MODULATING AGENTS., 29 July 2011 (2011-07-29)Non-patent––Search report–